EWTXEdgewise Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+10% of shares).
Choppy, but holding above its 200-day average. Price is +10% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover. Up 18% since the previous count, up from 9.7% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How EWTX is trading
Edgewise Therapeutics, Inc. is +156% over the past year while the S&P 500 is +16%: 140 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +10%
vs 200-day average · a clear uptrend
- RSI (14)
- 45
RSI (14) · neutral
- Below its 52-week high
- 19%
Below its 52-week high
Details›
- Last close2026-10-23
- $39.27
- 1 monthS&P 500 −0.94%
- −4.6%
- 1 yearS&P 500 +16%
- +156%
- 5 yearsS&P 500 +86%
- +131%
- vs 50-day average$41.83
- −6.1%
- 52-week high
- $48.34
- 52-week low
- $14.89
- Annualised volatility
- 71%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $2.9M
| Year | Return |
|---|---|
| 2026 (year to date) | +58% |
| 2025 | −7.1% |
| 2024 | +144% |
| 2023 | +22% |
| 2022 | −41% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 4 of 5 | +17% |
| Feb | 5 | 1 of 5 | −5.3% |
| Mar | 5 | 2 of 5 | −9.8% |
| Apr | 6 | 1 of 6 | −4.5% |
| May | 6 | 3 of 6 | −2.1% |
| Jun | 6 | 3 of 6 | −1.0% |
| Jul | 6 | 2 of 6 | +0.01% |
| Aug | 6 | 4 of 6 | −0.85% |
| Sep | 6 | 3 of 6 | +7.7% |
| Oct | 6 | 3 of 6 | +7.2% |
| Nov | 5 | 2 of 5 | +7.1% |
| Dec | 5 | 1 of 5 | +8.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.